In addition, more work on validating the therapeutic effects of in vivo knockdown of RPPH1 in animals is warranted to substantiate the potential of the RPPH1/miR-330-5p axis-targeted therapy in AML patients. The gene discussed is RPPH1; the disease is acute myeloid leukemia.